Citigroup says to buy the dip in Bristol-Myers (BMY +1.5%). The firm believes the FDA's complete...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

Citigroup says to buy the dip in Bristol-Myers (BMY +1.5%). The firm believes the FDA's complete response letter on Eliquis will be resolved quickly and should delay the U.S. launch of the drug by only by a couple of months. The delay won't significantly change its estimates, and the it maintains its a $40 price target on the shares.